SCHEMBL1662528

SCHEMBL1662528

COc1cc(F)cc(CBr)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAOB P27338 2/20 0.39
TAAR1 Q96RJ0 1/20 0.38
TSHR P16473 2/20 0.37
FFAR4 Q5NUL3 1/20 0.36
ALKBH1 Q13686 1/20 0.36
NQO2 P16083 1/20 0.36
CYP19A1 P11511 1/20 0.36
MAPK1 P28482 1/20 0.36
CALM1 P0DP23 1/20 0.36
GRIN2D O15399 1/20 0.35
GRIN3B O60391 1/20 0.35
GRIN1 Q05586 1/20 0.35
GRIN2A Q12879 1/20 0.35
GRIN2B Q13224 1/20 0.35
GRIN2C Q14957 1/20 0.35
GRIN3A Q8TCU5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29359230 1.00 CYP4F2 (0.41) CYP4F2CYP4A11ALDH1A1MAOBTAAR1
SCHEMBL1742765 0.84 ALDH1A1 (0.50) ALDH1A1TAAR1TSHRCYP19A1MAPK1
SCHEMBL627823 0.84 ALDH1A1 (0.58) ALDH1A1TSHRCYP19A1MAPK1CALM1
SCHEMBL467237 0.82 ALDH1A1 (0.55) ALDH1A1TSHRCYP19A1MAPK1CALM1
SCHEMBL241171 0.81 PTGS2 (0.43) CYP4F2CYP4A11ALDH1A1MAOBTAAR1
SCHEMBL7664052 0.79 CYP4F2 (0.44) CYP4F2CYP4A11ALDH1A1MAOBTAAR1
SCHEMBL3685037 0.79 TAAR1 (0.47) CYP4F2CYP4A11ALDH1A1MAOBTAAR1
SCHEMBL13074373 0.79 ALDH1A1 (0.40) ALDH1A1TSHRCYP19A1MAPK1CALM1
SCHEMBL16958198 0.79 CYP4F2 (0.41) CYP4F2CYP4A11ALDH1A1MAOBTAAR1
SCHEMBL585906 0.79 CYP4F2 (0.62) CYP4F2CYP4A11ALDH1A1MAOBTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12528767-B2 HDAC6 inhibitors and uses thereof EIKONIZO THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-12428413-B2 Rho kinase inhibitors and compositions and methods of use thereof CHDI FOUNDATION, INC. (US) 2025-09-30 US disclosed
US-12384813-B2 Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates MIRECA MEDICINES GMBH (DE) 2025-08-12 US disclosed
US-12180221-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-12-31 US disclosed
CN-118084800-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-118084801-A Compounds and uses thereof 詹森药业有限公司 2024-05-28 CN disclosed
CN-112312913-B Compounds and uses thereof 詹森药业有限公司 2024-03-08 CN disclosed
EP-3990442-B1 RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF CHDI FOUNDATION INC (US) 2024-02-28 EP disclosed
US-20230242568-A1 POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES MIRECA MEDICINES GMBH (DE) 2023-08-03 US disclosed
US-20230078764-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 US disclosed
US-20160024059-A1 HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-28 US disclosed
US-20160024059-A1 HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-28 US disclosed
WO-2016014463-A1 HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-01-28 WO disclosed
US-9242987-B2 Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors CELLZOME LIMITED (GB) 2016-01-26 US disclosed
US-20150291595-A1 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS ALMIRALL, S.A. (ES) 2015-10-15 US disclosed
EP-2909207-A1 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS Almirall S.A. (ES) 2015-08-26 EP disclosed
WO-2014060432-A1 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS ALMIRALL, S.A. (ES) 2014-04-24 WO disclosed
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2012-10-04 US disclosed
EP-2491039-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS Cellzome Limited (GB) 2012-08-29 EP disclosed
WO-2011048082-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024059-A1 HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE ADCY9, ADCY7, GUCY1B1 CYP4F2 1468/4885CYP4A11 508/4885ALDH1A1 1563/4885
US-12428413-B2 Rho kinase inhibitors and compositions and methods of use thereof ROCK1, ROCK2, RHOA CYP4F2 4589/4885CYP4A11 4563/4885ALDH1A1 4692/4885
US-20230242568-A1 POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES PRKG1, PRKG2, PRKAG3 CYP4F2 4213/4885CYP4A11 4310/4885ALDH1A1 3952/4885
US-20120252779-A1 HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS JAK1, JAK3, JAK2 CYP4F2 1917/4885CYP4A11 1734/4885ALDH1A1 2233/4885
US-12384813-B2 Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates PRKG1, PRKG2, PRKAG3 CYP4F2 4201/4885CYP4A11 4325/4885ALDH1A1 3912/4885
US-20230078764-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 CYP4F2 1826/4885CYP4A11 1283/4885ALDH1A1 293/4885
US-20150291595-A1 PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS PIK3CB, PIK3CD, PIK3CA CYP4F2 541/4885CYP4A11 755/4885ALDH1A1 2513/4885
US-12180221-B2 Compounds and uses thereof NLN, ACHE, CLN6 CYP4F2 1283/4885CYP4A11 898/4885ALDH1A1 656/4885
US-12528767-B2 HDAC6 inhibitors and uses thereof HDAC6, HDAC1, HDAC11 CYP4F2 4610/4885CYP4A11 4584/4885ALDH1A1 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.